ChronicleBio

ChronicleBio is a techbio company building what it describes as an AI-ready data platform for complex chronic and neuroimmune conditions, including postural orthostatic tachycardia syndrome (POTS), ME/CFS, Long COVID, MCAS, Sjögren's and Lyme-related illnesses. The company collects blood and other biospecimens from patients through partner clinics and research collaborations, stores them in a research-grade biobank, and generates longitudinal, multi-modal datasets spanning whole-genome sequencing, epigenetics, RNA sequencing, immune profiling, proteomics, metabolomics, clinical records and patient-reported outcomes.

The core thesis is that conditions named after their symptoms often encompass several mechanistically distinct sub-diseases, or endotypes, which causes clinical trials to fail because responders and non-responders offset one another. ChronicleBio applies AI to its multi-omic data to identify biologically coherent patient subgroups, then aims to map those subgroups to existing or clinical-stage drugs and to partner with biotech and pharmaceutical sponsors on new therapeutics. Management stated in August 2026 that it had identified five sub-diseases within POTS with differing underlying biology and intended to begin testing existing drugs in its patient population before the end of that year.

The company also describes a decentralized clinical trial network intended to give drug developers real-world access to patients and clinicians, and planned a consumer-facing element in which mobile phlebotomy trucks perform home blood draws in exchange for participants contributing biological data.

Founding story

ChronicleBio was founded by Fidji Simo, Rohit Gupta and Rishi Reddy, each of whom has a chronic disease or a family member with one. Simo, previously a Meta executive overseeing the Facebook app and then CEO of Instacart, which she took public in 2023, before joining OpenAI in 2025, has POTS and has said the complexity and multisystem nature of these diseases made them very difficult to address without AI. Gupta, the CEO, is a biobanking and precision medicine leader who previously oversaw centers at Stanford and UCSF. Reddy, Executive Chairman, comes from Tarsadia Investments with a background in health and life sciences investing. Both Simo and Reddy have been diagnosed with at least one of the conditions the company studies, and Gupta's family is affected by neuroimmune disorders.

Business model

ChronicleBio generates proprietary multi-omic and clinical datasets from patients with neuroimmune conditions and uses them to identify disease subgroups and biomarkers. It describes strategic partnerships with clinics, research consortia and biotech sponsors seeking to work in hard-to-treat therapeutic areas, plans to test existing drugs in its stratified patient populations, and intends to partner with biotech and pharmaceutical companies to develop new drugs. It also operates a decentralized clinical trial network to accelerate drug development through real-world access to patients and clinicians.

Sources describe partnerships with clinics, research consortia and biotech sponsors and a decentralized clinical trial network, and plans to co-develop drugs with biotech and pharma partners, but do not specify pricing or revenue terms.

Traction

In its first year the company reported 890 blood draws from 709 patients in Utah, Arizona, Texas and India, more than 3,500 tubes of blood in its biobank, and 153 terabytes of extracted data. It said it had identified five sub-diseases within POTS with distinct underlying biology and planned to begin testing existing drugs in its patient population before the end of 2026. Its platform was described at launch as already in use across multiple clinics in the U.S. and India, with research collaborations involving thousands of patients contributing data and biosamples.

Latest developments

In June 2026 ChronicleBio named John Mumm as Chief Scientific Officer and highlighted Yambazi Banda as Head of Platform. In August 2026 Fidji Simo, who had left OpenAI in early July 2026, discussed the company's progress publicly, disclosing $15 million raised to date, 3,500 tubes of banked blood, the identification of five POTS sub-diseases, a recent move into a Menlo Park headquarters and lab, and an August 11, 2026 launch of a home mobile-phlebotomy sign-up program.